Cardiovascular Diseases
The research centre is evaluating innovative treatments aimed at reducing cardiovascular risk in patients with atherosclerotic cardiovascular disease and related conditions.
- Atherosclerosis and cardiovascular disease
- Chronic kidney disease with systemic inflammation
- Major adverse cardiovascular events in high‑risk diabetes
Trials focus on improving survival, lowering blood pressure, and preventing heart attacks through novel antibodies and oral agents.
Immune System Disorders
Studies target inflammatory skin and airway conditions, testing next‑generation biologics for moderate‑to‑severe plaque psoriasis and related diseases.
- Atopic dermatitis
- Moderate‑to‑severe plaque psoriasis
- Psoriatic arthritis (axial and peripheral)
- Severe eosinophilic asthma
The goal is to assess efficacy, safety, and optimal dosing of IL‑23, IL‑17, and JAK pathway inhibitors.
Cancer Research
The site conducts trials in solid tumours, exploring immunotherapy combinations for non‑small cell lung cancer and breast cancer subtypes.
- Advanced non‑small cell lung cancer (NSCLC)
- Triple‑negative breast cancer
- Hormone‑receptor‑positive, HER2‑negative early breast cancer
- Metastatic NSCLC without actionable mutations
Objectives include extending progression‑free survival and overall survival by adding novel antibodies to standard chemotherapy.
Nervous System Disorders
Research addresses neuropathic pain associated with metabolic disease, evaluating new agents for diabetic peripheral neuropathy.
- Diabetic peripheral neuropathic pain
Trials measure pain intensity reduction and long‑term tolerability of emerging analgesic compounds.
Metabolic & Nutritional Health
Multiple studies target obesity and glucose regulation, testing oral and injectable therapies for type 2 diabetes and weight management.
- Type 2 diabetes mellitus
- Obesity and overweight
- Chronic weight management
- Glycemic control in patients on SGLT2 inhibitors
The aim is to achieve better HbA1c reduction, significant weight loss, and lower cardiovascular risk with new drug combinations.
Respiratory Diseases
A focused programme investigates biologic therapies for severe asthma, particularly the eosinophilic phenotype.
- Severe eosinophilic asthma
Objectives include assessing long‑term safety and reduction in exacerbations when added to standard inhaled treatments.
Dermatology & Connective Tissue
The centre evaluates dose‑adjusted regimens for skin‑focused immune diseases, such as moderate‑to‑severe atopic dermatitis.
- Moderate‑to‑severe atopic dermatitis
- Plaque psoriasis
- Psoriatic arthritis
Studies compare new monoclonal antibodies and oral JAK inhibitors to improve skin clearance and joint symptoms.
